Clinical-stage biotech company Eccogene has raised CNY180m ($25m) in series B equity financing to support the development of its clinical-stage pipeline. The funding round was led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, and included new investors Rockbleu Capital, YuFu Investment, Huajin Capital and Elikon Venture, as well as existing backers Delos Capital, Oriza Seed Capital and Qingsong Capital. Proceeds will be used to support the development of Eccogene's clinical-stage programmes including ECC5004 for obesity and type 2 diabetes; ECC4703 for NASH and lipid disorders; and ECC0509 for immunological and metabolic diseases.
Keywords: Eccogene, biotech, metabolic diseases, series B financing, clinical-stage pipeline
Additional related sentence: Eccogene aims to address unmet medical needs globally with innovative therapeutic solutions focusing on translational medicine for metabolic and immune-related diseases.